EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma
نویسندگان
چکیده
منابع مشابه
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma
Purpose. This study investigates the efficacy and toxicity of daily oral etoposide in chemotherapy for non-heavily pretreated advanced and metastatic soft tissue sarcoma (STS).Subjects. Twenty-seven patients with progressive and measurable disease were treated. Median age was 53 years (range 20-71 years) and performance status WHO 0 or 1. Histologies included mainly leiomyosarcoma (8), malignan...
متن کاملAchievements of the EORTC Soft Tissue and Bone Sarcoma Group
The EORTC Soft Tissue and Bone Sarcoma Group (STBSG) develops, stimulates, and coordinates studies on all aspects of sarcomas, and over the years they have made significant achievements in the research and treatment of sarcomas. Through EORTC trials 62001, 62005, 62024, and 62063, they established imatinib in the treatment of gastrointestinal stromal tumors (GIST). Because the STBSG has conduct...
متن کاملPhase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Docetaxel has been evaluated in six tumour types in a total of 189 patients entered into phase II studies. Treatment consisted of a 1 h intravenous infusion of docetaxel 100 mg/m2 repeated every 3 weeks. No premedication was administered for possible hypersensitivity reactions. Docetaxel was found to be effective as first-line chemotherapy for head and neck cancer (response rate 44%) gastric ca...
متن کاملA Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma
Purpose. The study was performed to assess the antitumour activity and toxicity of a 72-h continuous infusion of single-agent etoposide as second-line treatment for patients with locally advanced or metastatic soft tissue sarcoma (STS), following reports of substantial activity using this schedule of etoposide administration as first-line treatment in combination with ifosfamide.Patients/method...
متن کاملGefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group.
9517 Background: Synovial sarcomas (SyS) have been reported to overexpress HER1 in gene expression profile experiments and immunohistochemistry. Gefitinib, a specific inhibitor of HER1, was therefore tested in advanced or metastatic SyS failing doxorubicin (Doxo) ± ifosfamide (Ifo). METHODS Patients (pts) with advanced or metastatic SyS expressing HER1 using IHC were included. The principal i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sarcoma
سال: 1997
ISSN: 1357-714X,1369-1643
DOI: 10.1080/13577149778371